Pyridinone dicarboxamide selective BD2 inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune and inflammatory conditions, such as rheumatoid arthritis, and cancer lack effective bromodomain inhibitors that can selectively target Binding Domain 2 (BD2) of BET family proteins, limiting therapeutic options.
Innovation Solution
Development of specific compounds of formula (I) and their salts, which act as selective BD2 inhibitors, capable of treating autoimmune and inflammatory conditions, including rheumatoid arthritis, and cancer by modulating chromatin structure and gene transcription.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for autoimmune and inflammatory conditions are used, then existing therapeutic options are available, but effective bromodomain inhibitors that can selectively target BD2 are lacking
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features (R1, R2, R3, R4 substituents on the pyridinone core) that confer selective binding affinity for BD2 over other bromodomain subtypes. This localized optimization of molecular structure at specific positions enables the compound to distinguish and target BD2 with high selectivity while maintaining therapeutic effectiveness for autoimmune and inflammatory conditions.
2Adaptability or versatility
If selective BD2 inhibitors are developed, then new therapeutic options are provided, but the compound structure becomes more complex
Solution Approach 1:
The patent employs segmentation by dividing the BD2 binding interface into distinct molecular regions represented by separate substituent groups (R1, R2, R3, R4) on the pyridinone core. Each substituent can be independently optimized to interact with specific residues in the BD2 pocket, allowing the complex selectivity requirement to be broken down into manageable structural components that can be developed through systematic medicinal chemistry approaches.
Solution Approach 2:
The patent utilizes parameter changes by systematically varying the chemical properties of substituents (hydrophobicity, hydrogen bonding capacity, steric bulk) at different positions on the pyridinone scaffold. These parameter optimizations enable fine-tuning of the compound's selectivity profile for BD2 while managing the overall molecular complexity through rational design rather than trial-and-error approaches.
3Object-affected harmful factors
If compounds of formula (I) are used to inhibit BD2, then inflammatory responses are suppressed, but the mechanism involves complex chromatin structure modulation
Solution Approach 1:
The patent applies the taking out principle by extracting and inhibiting the specific BD2 domain function from the complex chromatin modulation machinery. By selectively blocking BD2's ability to recognize acetylated lysine residues on histones, the compound disrupts the transcriptional programs driven by BET proteins without requiring complete dismantling of chromatin structure, thereby suppressing inflammatory responses through a focused molecular intervention rather than global chromatin remodeling.
Data Source
AI summary
The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy